675 Anastrozole is an effective neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer irrespective of cerbB2 status

Milla-Santos, A.; Milla, L.; Calvo, N.; Portella, Jordi; Rallo, L.; Casanovas, J; Pons, M.; Rodés, Josep

doi:10.1016/s1359-6349(03)90706-3

Cited by 9 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although a larger study did not show a difference in OR between letrozole and tamoxifen in patients with HER2-positive status, the results are not directly comparable with those in the smaller-scale preoperative study because HER2 status was not determined on an excision biopsy, and the patients had metastatic disease [8]. The effectiveness of preoperative anastrozole in patients with HER2-positive and HER2-negative tumors has also been assessed [9][10][11]. Most recently, a randomized neoadjuvant trial of anastrozole versus tamoxifen versus the combination (Immediate Preoperative Arimidex, Tamoxifen or Combined with Tamoxifen, IMPACT) reported more responses in patients with ER-positive and HER2-positive tumors treated with anastrozole than with tamoxifen (Smith et al Neoadjuvant treatment of postmenopausal breast cancer with In TA01, we will test tumors to determine whether the relative benefit from tamoxifen and anastrozole in the adjuvant setting also differs according to HER2 status.…”

Section: Collection Of Specimens From Primary Tumors: Guiding Initialmentioning

confidence: 94%

Biomarker investigations from the ATAC trial: the role of TA01

Dowsett

2004

Breast Cancer Res Treat

View full text Add to dashboard Cite

cDNA arrays and proteomic analyses have allowed the rapid identification of specific genes and proteins implicated in multiple tumor types. These molecules must then be validated as clinically relevant prognostic and predictive markers, and this translational research is best conducted in the context of clinical trials. Outcomes data and clinical specimens collected in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) study, for example, can now be used to compare the expression of biomarkers with clinical outcomes. In this study, adjuvant tamoxifen and anastrozole ('Arimidex') were compared alone and in combination in more than 9000 women with breast cancer. Anastrozole was found to be superior to tamoxifen in terms of disease-free survival, time to recurrence, and reduction in the incidence of contralateral tumors. Importantly, tissue specimens from surgical excision, local relapse, and contralateral breast cancer were collected and paraffin-embedded for storage. In the TA01 (TransATAC) program, these specimens will be studied (after obtaining patient consent) using tissue microarrays; tissue biopsy cores 0.6 mm in diameter will be removed from donor blocks and placed on recipient blocks, which will be sectioned to allow the simultaneous analysis of the same samples for multiple biomarkers. These analyses can help determine differential benefits of treatment with anastrozole or tamoxifen, depending on the expression of particular biomarkers in tumor cells. This research also should clarify de novo and acquired resistance mechanisms, and the validation of relevant molecular pathways could guide the development of new drugs. Ultimately, the TA01 program has the potential to favorably impact treatment choices for breast cancer.

show abstract

Section: Collection Of Specimens From Primary Tumors: Guiding Initialmentioning

confidence: 94%

Biomarker investigations from the ATAC trial: the role of TA01

Dowsett

2004

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…They are therefore now being tested as primary systemic treatment instead of tamoxifen, similar to the adjuvant setting [18,19]. In these approaches, response rates of 40% and 60% have been reported in randomized clinical trials for letrozole and anastrazole, respectively [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

Mlineritsch

Tausch

Singer

et al. 2007

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Otros estudios fase II han confirmado estos hallazgos con respuestas clínicas de 37 a 100%, sin embargo, los niveles de cPR con TE rara vez superan el 5% [27][28][29][30] .…”

Section: Ia Versus Tamoxifenounclassified

Terapia endocrina neoadyuvante en cáncer de mama, una alternativa de tratamiento e investigación

et al. 2013

View full text Add to dashboard Cite

Neoadyuvant endocrine therapy in breast cancerE l cáncer de mama (CM) es la primera causa de muerte por neoplasias en mujeres chilenas 1 . El amplio uso de métodos de screening, con el consiguiente aumento en las tasas de diagnóstico precoz, ha mejorado su pronóstico 2 . Nuevos esquemas y drogas de quimioterapia (QT) citotóxica, además del uso de anticuerpos monoclonales en tumores que expresan el receptor del factor de crecimiento epidérmico tipo 2 (HER2+), han contribuido también a esta mejoría, especialmente en tumores RE negativos y HER2+ 3 . Sin embargo, la resistencia al tratamiento y recaídas de la enfermedad son frecuentes.La búsqueda de mejores terapias se basa finalmente en resultados obtenidos de estudios clínicos fase III, los que comparan distintos tipos de tratamiento adyuvante (postoperatorio), teniendo como objetivo primario la sobrevida global (SG). Otra alternativa es medir los efectos de la terapia sisté-mica en el ámbito preoperatorio (neoadyuvancia), evaluando cambios inducidos por el tratamiento en el corto plazo sobre bio-marcadores predefinidos que están relacionados con la SG. De estos, la respuesta patológica (PR) obtenida luego de terapia neoadyuvante ha sido utilizada para predecir la SG de pacientes con CM 4 . Varios estudios utilizando QT preoperatoria en pacientes con tumores localmente avanzados han demostrado que el tratamiento neoadyuvante aumenta la posibilidad de conservación de la mama y mejora los resultados quirúrgicos, sin detrimento en la sobrevida, en relación al tratamiento con QT posoperatoria [4][5][6] .Dado que más del 80% de los CM expresan el receptor estrogénico (RE), tratamientos destinados a modular su actividad son parte fundamental en su manejo. La terapia endocrina (TE) adyuvante logra disminuir la recurrencia de la enfermedad y mejorar la SG de tumores RE+; parece lógico, por tanto, que la TE orientada molecularmente al RE y que ha demostrado beneficio en adyuvancia, se utilice también en el escenario preoperatorio en tumores RE+ 7 .

show abstract

675 Anastrozole is an effective neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer irrespective of cerbB2 status

Cited by 9 publications

References 0 publications

Biomarker investigations from the ATAC trial: the role of TA01

Biomarker investigations from the ATAC trial: the role of TA01

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

Terapia endocrina neoadyuvante en cáncer de mama, una alternativa de tratamiento e investigación

Contact Info

Product

Resources

About